Figure S4 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung Cancer
Elena P. Ivanova(RMIT University), Pasi A. Jänne(Harvard University), Irmina Diala(Puma Biotechnology (United States)), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Kwok‐Kin Wong(NYU Langone Health), Magda Bahcall(Harvard University), Geoffrey R. Oxnard(Foundation Medicine (United States)), Thanh U. Barbie(Brigham and Women's Hospital), Mari Kuraguchi(Beijing Biocytogen (China)), Amir A. Aref(Dana-Farber Cancer Institute), Luke J. Taus(Dana-Farber Cancer Institute), Cloud P. Paweletz(Massachusetts General Hospital), Shengwu Liu(Broad Institute), David A. Barbie(Dana-Farber Cancer Institute), Andrew Portell(Massachusetts General Hospital), Jacob J. Haworth(Dana-Farber Cancer Institute), Shuai Li(Second Hospital of Tianjin Medical University), Ting Chen(Tianjin University of Traditional Chinese Medicine), Man Xu, Emily S. Chambers(Dana-Farber Cancer Institute), Jihyun Choi, Alshad S. Lalani(Puma Biotechnology (United States))
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k